Latest filing published 17 May 2024 for eFFECTOR Therapeutics, Inc..
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- -23.5%Entry US$40.88 · Close at T+365 US$31.25
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Stephen T. Worland: trading record in brief
Stephen T. Worland is a declared insider at 4 companies (chief executive); the most frequent names are Anadys Pharmaceuticals Inc, eFFECTOR Therapeutics, Inc. and GenMark Diagnostics, Inc. The record holds 29 filings, for trades running from 2 March 2006 to 15 May 2024.
On the open market, the record shows 9 purchases worth €250k and 3 sales worth €122k. The net balance comes to €128k on the buying side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 11 share grants and 6 option exercises.
Half of the purchases are above €4,757 and half below.
The record was last updated on 17 May 2024 with a share grant in eFFECTOR Therapeutics, Inc. The last purchase on record was published on 9 June 2022, which is 1,613 days ago. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Stephen T. Worland
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 1,806 shares@ €1.54555.0% of flowCommon StockSEC:0000950170-24-061593:0
- 5,979 shares@ €0.45714.9% of flowCommon StockSEC:0001209191-23-055557:0
- 33,799 shares@ €0.473528.9% of flowCommon StockSEC:0001209191-23-045499:0
- 6,401 shares@ €0.42214.9% of flowCommon StockSEC:0001209191-23-029646:0
- 6,047 shares@ €0.45395.0% of flowCommon StockSEC:0001209191-22-057379:0
- 20,000 shares@ US$1.37100.0% of flowCommon StockSEC:0001209191-22-035277:0Canonical exit: 5 Sept 2022 (T+90)
- 1,837 shares@ €1.4749.6% of flowCommon StockSEC:0001209191-22-029890:0
- 50,000 shares@ US$10.000.0% of flowCommon StockSEC:0001209191-21-053686:1
- 193,141 sharesCommon StockSEC:0001209191-21-053686:2
- 512,339 sharesCommon StockSEC:0001209191-21-053686:0
- 7,500 shares0Common StockSEC:0001209191-16-125312:0
- 5,677 shares0Common StockSEC:0001181431-14-022185:0
- 14,922 shares0Common StockSEC:0001181431-13-030378:0
- 47 shares@ US$2.95Common StockSEC:0001209191-08-034189:0
- 17,651 shares@ US$2.95Common StockSEC:0001209191-08-034189:1
- 16,200 shares@ US$2.95Common StockSEC:0001209191-08-034189:2
- 124,564 shares@ US$2.00Common StockSEC:0001209191-07-051841:0Canonical exit: 28 Nov 2007 (T+90)
- 6,219 shares@ US$2.12Common StockSEC:0001209191-07-051841:1Canonical exit: 29 Nov 2007 (T+90)
- 3,120 shares@ US$2.08Common StockSEC:0001209191-07-051841:2Canonical exit: 29 Nov 2007 (T+90)
- 1,800 shares@ US$2.10Common StockSEC:0001209191-07-051841:3Canonical exit: 29 Nov 2007 (T+90)
- 1,042 shares@ US$2.13Common StockSEC:0001209191-07-051841:4Canonical exit: 29 Nov 2007 (T+90)
- 19 shares@ US$2.15Common StockSEC:0001209191-07-051841:5Canonical exit: 29 Nov 2007 (T+90)
- 12,341 shares@ US$2.35Common StockSEC:0001209191-07-051841:6Canonical exit: 3 Dec 2007 (T+90)
- 895 shares@ US$2.34Common StockSEC:0001209191-07-051841:7Canonical exit: 3 Dec 2007 (T+90)
- 25,000 shares@ US$2.95Common StockSEC:0001209191-07-003713:0
25 of 27 declarations
